[1] |
Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity[J]. Clin Infect Dis,2004,38(1):e10-e14.
|
[2] |
Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans[J]. Blood,2004,103(2):673-675.
|
[3] |
Kampitak T, Suwanpimolkul G, Browne S, et al. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature[J]. Infection,2011,39(1):65-71.
|
[4] |
Tang BS, Chan JF, Chen M,et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon[J]. Clin Vaccine Immunol,2010,17(7):1132-1138.
|
[5] |
Aoki A, Sakagami T, Yoshizawa K, et al. Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease[J]. Clin Infect Dis,2018,66(8): 1239-1245.
|
[6] |
Guo J, Ning XQ, Ding JY, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections[J]. J Exp Med,2020,217(12):e20190502.
|
[7] |
Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in Thailand and the United States[J].Clin Infect Dis,2020,71(1):53-62.
|
[8] |
Chen YP, Yen YS, Chen TY, et al. Systemic Mycobacterium kansasii infection mimicking peripheral T-cell lymphoma[J]. Apmis,2008,116(9):850-858.
|
[9] |
侯志飞,赵学森. 干扰素诱导跨膜蛋白抗病毒机制的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2018,12(3):212-215.
|
[10] |
Chan JF, Trendell-Smith NJ, Chan JC, et al. Reactive and infective dermatoses associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: Sweet’s syndrome and beyond[J]. Dermatology,2013,226(2):157-166.
|
[11] |
赖冠廷,梁小娜,宾雁飞, 等. 抗γ-干扰素自身抗体阳性患者5例临床特征分析并文献复习[J]. 中国实用内科杂志,2020,40(10):840-849.
|
[12] |
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases[J]. Biomol Concepts,2018,9(1):64-79.
|
[13] |
佟晔,张昕宇,周志安, 等. 以非伤寒沙门菌菌血症首诊的非霍奇金淋巴瘤一例[J/CD]. 中华实验和临床感染病杂志(电子版),2020,14(2):167-171.
|
[14] |
Krisnawati DI, Liu YC, Lee YJ, et al. Blockade effects of anti-interferon- (IFN-) γ autoantibodies on IFN-γ-regulated antimicrobial immunity[J]. J Immunol Res,2019,2019:1629258.
|
[15] |
Wu UI, Wang JT, Sheng WH, et al. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies[J]. Clin Microbiol Infect,2020,26(12):1684.
|
[16] |
Murcia MI, Tortoli E, Menendez MC, et al. Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant[J]. Int J Syst Evol Microbiol,2006,56(Pt 9):2049-2054.
|
[17] |
Maurer FP, Pohle P, Kernbach M, et al. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex[J]. Clin Microbiol Infect,2019,25(3):379.
|
[18] |
Rujirachun P, Sangwongwanich J, Chayakulkeeree M. Triple infection with Cryptococcus, varicella-zoster virus, and Mycobacterium abscessus in a patient with anti-interferon-gamma autoantibodies: a case report[J]. BMC Infect Dis,2020,20(1):232.
|
[19] |
Czaja CA, Merkel PA, Chan ED, et al. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-gamma autoantibody[J]. Clin Infect Dis,2014,58(6):e115-118.
|
[20] |
Browne SK, Zaman R, Sampaio EP, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection[J]. Blood,2012,119(17):3933-3939.
|
[21] |
Ochoa S, Ding L, Kreuzburg S, et al. Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-γ autoantibodies[J]. Clin Infect Dis,2021,72(12):2206-2208.
|
[22] |
Rocco JM, Rosen LB, Hong GH, et al. Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies[J]. J Transl Autoimmun,2021,4:100102.
|
[23] |
Harada M, Furuhashi K, Karayama M, et al. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-gamma autoantibody associated disseminated nontuberculous mycobacterial infection[J]. J Infect Chemother,2021,27(2):373-378.
|
[24] |
Chetchotisakd P, Anunnatsiri S, Nanagara R, et al. Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Mycobacterium abscessus infection[J]. J Immunol Res,2018,2018:6473629.
|
[25] |
Jutivorakool K, Sittiwattanawong P, Kantikosum K, et al. Skin manifestations in patients with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: A relationship with systemic infections[J]. Acta Derm Venereol,2018,98(8):742-747.
|